Abstract
Anthracycline-related cardiotoxicity is an important dose-limiting toxicity for Hodgkin lymphoma (HL) treatment. This study aimed to assess the efficacy and safety of pegylated liposomal doxorubicin (PLD) for HL treatment. Patients with newly diagnosed HL treated with at least two cycles of PLD-containing chemotherapy were retrospectively analyzed. The dosing and scheduling of the PLD-containing regimen (the PBVD regimen) were as follows: PLD 25 mg/m2, vincristine 1.4 mg/m2 (maximum dose of 2 mg), bleomycin 10 mg/m2, and dacarbazine 375 mg/m2 at days l and 15, repeated every 28 days. Forty-six HL patients were analyzed. The median age was 41.5 years (range 12-77 years), with a male/female ratio of 0.9:1. Fourteen (30%) patients had an Eastern Cooperative Oncology Group (ECOG) performance status score > 1, and 32 (70%) had a history of cardiovascular disease (CVD) or related risk factors. The median chemotherapy cycle number with the PBVD regimen was 6 (range, 2-8). The overall response rate (ORR) was 91% for the whole cohort; 35 (76%) patients achieved complete remission (CR), and 7 (15%) achieved partial remission. The efficacy of the PBVD regimen was similar in patients with or without CVD or related risk factors (ORR 93% vs....Continue Reading
References
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BartlettUNKNOWN Cancer Leukemia Group B
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J HoskinPeter W M Johnson
Jun 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diana WongsoAndreas Engert
Feb 26, 2015·Journal of the National Cancer Institute·David J CutterBerthe M P Aleman
Apr 5, 2015·Haematologica·Anne-Sophie MichalletPauline Brice
Apr 29, 2015·JAMA Internal Medicine·Frederika A van NimwegenFlora E van Leeuwen
Mar 17, 2016·Blood·Steven H SwerdlowElaine S Jaffe
Mar 22, 2016·Cancer Medicine·Matthew KoshyUsama Mahmood
Sep 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Talya SalzChristoffer Johansen
Oct 25, 2017·Lancet·Peter BorchmannAndreas Engert
Dec 2, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BuskeUNKNOWN ESMO Lymphoma Consensus Conference Panel Members
Jan 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea GallaminiAlessandro Rambaldi
Jan 31, 2018·British Journal of Cancer·Simone de VriesFlora E van Leeuwen
Mar 6, 2019·Journal of Hematology & Oncology·Weiping LiuUNKNOWN Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology, Union for China Lymphoma Investigators o
Jul 10, 2019·Leukemia & Lymphoma·Flavia SalviFrancesco Merli
Sep 29, 2019·JAMA Oncology·UNKNOWN Global Burden of Disease Cancer CollaborationChristopher J L Murray
Nov 21, 2019·Journal of Hematology & Oncology·Weiping LiuUNKNOWN Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology
Apr 14, 2020·Cancer Medicine·Weiping LiuJun Zhu